Azithromycin, also known as Zithromax, belongs to the class of medicines known as antibacterials orantibiotics. These medicines kill bacteria (small organisms that can cause infection in humans) or stopbacteria from growing. Patients with weakened immune systems, includingpeople with HIV, tend to have more frequent andmore serious bacterial infections. Azithromycinwas approved by the FDA on June 14, 1996, formany uses, including the prevention and treatmentof Mycobacterium avium complex (MAC) inpersons with advanced HIV infection. It is alsobeing investigated to see how well it works inpreventing other kinds of bacterial infections inpeople with HIV.
The vast majority of sinus infections are caused by viruses and should not be treated with antibiotics, suggest new guidelines released by the Infectious Diseases Society of America.
In the E coli outbreak in Germany in May 2011, treatment with azithromycin was associated with a lower frequency of long-term carriage of the bacteria and shorter duration of shedding of the bacteria in stool specimens, according to a study in the March 14 issue of JAMA.
"Findings that a one-time oral treatment to cure yaws, a neglected tropical disease, is as effective as the currently recommended penicillin injection have prompted the World Health Organization (WHO) to convene a meeting on how the disease may be wiped out," IRIN reports.
InSite Vision Incorporated today announced that the University of California, San Francisco (UCSF) has appealed the judgment of the United States Patent and Trademark Office (USPTO) panel that found in favor of the Company in its patent interference litigation with UCSF.
A UCSF study shows a popular treatment for a potentially blinding eye infection is just as effective if given every six months versus annually. This randomized study on trachoma, the leading cause of infection-caused blindness in the world, could potentially treat twice the number of patients using the same amount of medication.
They come out in the spring, and each year they spread further - the ticks. Thirty percent of them transmit borrelia pathogens, the causative agent of Lyme borreliosis that can damage joints and organs.
Vitamin D levels are not related to acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in patients with severe COPD, according to a large prospective cohort study involving 973 North American patients. The findings were published online ahead of the print edition of the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.
Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, announced the financial results for the Fiscal Year 2011.
Cempra Pharmaceuticals today announced abstracts to be presented on its fourth generation macrolide and novel fluoroketolide antibiotic, solithromycin (CEM-101), at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17 to 20, 2011, in Chicago. The abstracts provide additional data that demonstrate the safety and routes of administration of CEM-101, a new generation macrolide.
Blood-sucking ticks are not just a nuisance, they can also transmit dangerous diseases. One of them is Lyme disease, which is caused by bacteria of the genus Borrelia, and requires a course of treatment with antibiotics lasting several weeks. LMU researchers have come up with a quicker alternative.
Richard Casaburi, Ph.D., M.D., principal investigator at Los Angeles Biomedical Research Institute (LA BioMed), is co-author of a recent study that should help improve the condition for the millions of individuals who suffer from chronic obstructive pulmonary disease, better known as COPD.
A common antibiotic can help reduce the severe wheezing and other acute symptoms of chronic obstructive pulmonary disease, according to a large, multicenter clinical trial sponsored by the National Institutes of Health and conducted at the University of California, San Francisco (UCSF).
A common antibiotic added to the usual treatment plan for some patients with chronic obstructive pulmonary disease can reduce acute exacerbations — sudden onsets of worsened cough, wheezing and labored breathing — and improve quality of life, according to findings from the COPD Clinical Research Network reported in the Aug. 25, 2011, issue of the New England Journal of Medicine.
Azithromycin is an antibiotic that also has antiinflammatory properties. It is these antiinflammatory properties that are thought to account for the improvement in clinical outcome observed when patients with chronic lung diseases such as cystic fibrosis are treated long-term with azithromycin.
Physicians at University Hospitals (UH) Rainbow Babies and Children's Hospital are participating in two new clinical trials with the national research consortium AsthmaNet.
Japanese scientists have found a superbug strain of gonorrhea that’s resistant to all available antibiotics. This can pose a threat to public health worldwide, infectious disease experts say.
Inspire Pharmaceuticals, Inc. announced today financial results for the first quarter ended March 31, 2011, reporting a net loss of $17.6 million or per common share, as compared to a net loss of $14.8 million, or per common share, for the same period in 2010.
Cempra Pharmaceuticals, a developer of differentiated antibiotics, today announced an oral presentation showing that intravenous (IV) solithromycin demonstrates excellent tolerability and a favorable pharmacokinetic profile at IV doses up to 800 mg.
The University of Newcastle is now conducting a nationwide research program to help people with asthma better control their condition. This study will be testing the effectiveness of combining antibiotics with commonly used treatments in asthmatics. This news comes today on the World Asthma Day. Statistics show that commonly prescribed treatments and medications do not relieve the symptoms for about 10 per cent of asthma patients. It's thought about 80% of people with the condition suffer numerous symptoms, yet 80% say they believe they have it under control.
Merck, known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR") has expired in connection with the previously announced cash tender offer made by Monarch Transaction Corp., a wholly owned subsidiary of Merck, to purchase all of the outstanding shares of common stock of Inspire.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.